GOODWILL AND INTANGIBLE ASSETS

3 Months Ended

Oct. 31, 2012

Goodwill and Intangible Assets Disclosure [Abstract]

The following table presents goodwill, allocated by reportable segment.



	Oct 31, 2012		July 31, 2012
Life Sciences	$	180,172	$	178,359
Industrial	161,475		160,582
	$	341,647	$	338,941

Intangible assets, net, consist of the following:



	Oct 31, 2012
	Gross		Accumulated Amortization		Net
Patents and unpatented technology	$	127,662	$	68,530	$	59,132
Customer-related intangibles	94,803		16,222		78,581
Trademarks	13,201		5,555		7,646
Other	4,447		2,467		1,980
	$	240,113	$	92,774	$	147,339

	July 31, 2012
	Gross		Accumulated Amortization		Net
Patents and unpatented technology	$	125,938	$	65,262	$	60,676
Customer-related intangibles	93,901		13,323		80,578
Trademarks	13,104		5,269		7,835
Other	5,179		3,124		2,055
	$	238,122	$	86,978	$	151,144

The changes in both goodwill and intangible assets relate to the impact of changes in foreign exchange rates used to translate the goodwill and intangible assets contained in the financial statements of foreign subsidiaries using the rates at each respective balance sheet date.

Amortization expense from continuing operations for intangible assets for the three months ended October 31, 2012 and October 31, 2011 was $5,278 and $4,147, respectively (excluded is amortization expense included in discontinued operations for the three months ended October 31, 2011 of $45) . Amortization expense is estimated to be approximately $14,017 for the remainder of fiscal year 2013, $17,499 in fiscal year 2014, $15,645 in fiscal year 2015, $14,384 in fiscal year 2016, $14,304 in fiscal year 2017 and $14,185 in fiscal year 2018.

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References+ Details